{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:08:45Z","timestamp":1794647325543,"version":"4.9.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to characterize the safety and efficacy of filgotinib, lanraplenib and tirabrutinib in patients with active SS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre, double-blind study randomized patients with active primary or secondary SS [EULAR SS disease activity index (ESSDAI) \u22655) to receive filgotinib 200\u2009mg (Janus kinase-1 inhibitor), lanraplenib 30\u2009mg (spleen tyrosine kinase inhibitor), tirabrutinib 40\u2009mg (Bruton\u2019s tyrosine kinase inhibitor), or placebo. The composite primary end point was the week-12 proportion of patients fulfilling protocol-specified improvement criteria (based on CRP and SS-related symptoms). The EULAR SS patient-reported index (ESSPRI) and the ESSDAI change from baseline (CFB) were secondary end points. Exploratory end points included disease-related biomarkers. Treatment-emergent adverse events (AEs) represented safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean of the baseline ESSDAI was 10.1, and of ESSPRI was 6.2 in the 150 patients who were treated; 125 completed the 24-week placebo-controlled treatment period. At week 12, 43.3% of the filgotinib group achieved the primary end point (P\u2009=\u20090.17 vs placebo) vs 42.3% (P\u2009=\u20090.16), 34.7% (P\u2009=\u20090.33), and 26.7% of lanraplenib, tirabrutinib, and placebo groups, respectively. Neither secondary end point was met. Biomarker reductions included immunoglobulins classically associated with SS disease activity. Filgotinib ESSDAI CFB appeared more pronounced in subgroups with baseline ESSDAI \u226514 or without DMARDs\/CSs. Most AEs were Grade 1 or 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Three drugs with disparate mechanisms were tested, but no significant differences vs placebo in primary or secondary end points were observed. These results may be considered hypothesis-generating, given the drug tolerability, subgroup analysis, and biomarker findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov, NCT03100942.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac167","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T09:11:17Z","timestamp":1649063477000},"page":"4797-4808","source":"Crossref","is-referenced-by-count":80,"title":["Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study"],"prefix":"10.1093","volume":"61","author":[{"given":"Elizabeth","family":"Price","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Great Western Hospital , Swindon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bombardieri","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London , London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research , Duncansville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Matzkies","sequence":"additional","affiliation":[{"name":"Clinical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana\u00a0","family":"Gurtovaya","sequence":"additional","affiliation":[{"name":"Biostatistics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Pechonkina","sequence":"additional","affiliation":[{"name":"Clinical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Jiang","sequence":"additional","affiliation":[{"name":"Bioinformatics, Gilead Sciences, Inc. , Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Downie","sequence":"additional","affiliation":[{"name":"Bioinformatics, Gilead Sciences, Inc. , Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anubhav","family":"Mathur","sequence":"additional","affiliation":[{"name":"Clinical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Mozaffarian","sequence":"additional","affiliation":[{"name":"Clinical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelufar","family":"Mozaffarian","sequence":"additional","affiliation":[{"name":"Immunology Research & Development, Janssen Pharmaceuticals , Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Eric","family":"Gottenberg","sequence":"additional","affiliation":[{"name":"H\u00f4pitaux Universitaires de Strasbourg et Universit\u00e9 de Strasbourg, and Centre de R\u00e9f\u00e9rence pour les Maladies Auto-Immunes Syst\u00e9miques Rares, CNRS, IBMC, UPR3572 , Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"2022112912434907100_keac167-B1","first-page":"247","article-title":"The epidemiology of Sj\u00f6gren\u2019s syndrome","volume":"6","author":"Patel","year":"2014","journal-title":"Clin Epidemiol"},{"key":"2022112912434907100_keac167-B2","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1093\/rheumatology\/key370","article-title":"Health-related quality of life and costs in Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Miyamoto","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2022112912434907100_keac167-B3","first-page":"97","article-title":"Systemic manifestations of primary Sj\u00f6gren\u2019s syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients","volume":"37(Suppl 118","author":"Retamozo","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2022112912434907100_keac167-B4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clim.2019.04.009","article-title":"Sjogren\u2019s syndrome: an update on disease pathogenesis, clinical manifestations and treatment","volume":"203","author":"Vivino","year":"2019","journal-title":"Clin Immunol"},{"key":"2022112912434907100_keac167-B5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.autrev.2018.12.008","article-title":"The pipeline of targeted therapies under clinical development for primary Sj\u00f6gren\u2019s syndrome: a systematic review of trials","volume":"18","author":"Felten","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2022112912434907100_keac167-B6","first-page":"555","article-title":"Methotrexate in primary Sj\u00f6gren\u2019s syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"2022112912434907100_keac167-B7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"2022112912434907100_keac167-B8","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022112912434907100_keac167-B9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022112912434907100_keac167-B10","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10067-017-3822-3","article-title":"Primary Sj\u00f6gren\u2019s syndrome: extraglandular manifestations and hydroxychloroquine therapy","volume":"36","author":"Demarchi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2022112912434907100_keac167-B11","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2022112912434907100_keac167-B12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren\u2019s syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022112912434907100_keac167-B13","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren\u2019s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatology"},{"key":"2022112912434907100_keac167-B14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022112912434907100_keac167-B15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"2022112912434907100_keac167-B16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1601-0825.2009.01582.x","article-title":"Cytokines in Sj\u00f6gren\u2019s syndrome","volume":"15","author":"Roescher","year":"2009","journal-title":"Oral Dis"},{"key":"2022112912434907100_keac167-B17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/art.40059","article-title":"Enhanced Bruton\u2019s tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease","volume":"69","author":"Corneth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022112912434907100_keac167-B18","doi-asserted-by":"crossref","first-page":"e12662","DOI":"10.1111\/sji.12662","article-title":"Transcription profiling of peripheral B cells in antibody-positive primary Sj\u00f6gren\u2019s syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature","volume":"87","author":"Imgenberg-Kreuz","year":"2018","journal-title":"Scand J Immunol"},{"key":"2022112912434907100_keac167-B19","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/rheumatology\/kez142","article-title":"Treatment of Sj\u00f6gren\u2019s syndrome: current therapy and future directions","volume":"60","author":"Fox","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2022112912434907100_keac167-B20","author":"Jyseleca\u00ae (Filgotinib maleate tablets)","year":"2020"},{"key":"2022112912434907100_keac167-B21","volume-title":"Summary of Product Characteristics","author":"Jyseleca\u00ae (filgotinib) 100 and 200 mg film-coated tablets","year":"2020"},{"key":"2022112912434907100_keac167-B22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/acsmedchemlett.9b00621","article-title":"Discovery of Lanraplenib (GS-9876): a once-daily spleen tyrosine kinase inhibitor for autoimmune diseases","volume":"11","author":"Blomgren","year":"2020","journal-title":"ACS Med Chem Letters"},{"key":"2022112912434907100_keac167-B23","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-020-01318-8","article-title":"Tirabrutinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"2022112912434907100_keac167-B24","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.23428","article-title":"An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus","volume":"58","author":"Bahjat","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022112912434907100_keac167-B25","doi-asserted-by":"crossref","first-page":"R243","DOI":"10.1186\/ar4086","article-title":"Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus","volume":"14","author":"Hutcheson","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2022112912434907100_keac167-B26","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.4049\/jimmunol.1301553","article-title":"Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis","volume":"191","author":"Rankin","year":"2013","journal-title":"J Immunol"},{"key":"2022112912434907100_keac167-B27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","article-title":"Defining disease activity states and clinically meaningful improvement in primary Sj\u00f6gren\u2019s syndrome with EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)","volume":"75","author":"Seror","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022112912434907100_keac167-B28","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2022112912434907100_keac167-B29","doi-asserted-by":"crossref","first-page":"e000022","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): a user guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"2022112912434907100_keac167-B30","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sj\u00f6gren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sj\u00f6gren\u2019s syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022112912434907100_keac167-B31","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3899\/jrheum.160185","article-title":"The risk of deep venous thrombosis and pulmonary embolism in primary Sj\u00f6gren syndrome: a general population-based study","volume":"44","author":"Avina-Zubieta","year":"2017","journal-title":"J Rheumatol"},{"key":"2022112912434907100_keac167-B32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022112912434907100_keac167-B33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12959-015-0043-3","article-title":"Systemic lupus erythematosus and thrombosis","volume":"13","author":"Bazzan","year":"2015","journal-title":"Thromb J"},{"key":"2022112912434907100_keac167-B34","author":"Rigel Pharmaceuticals Inc","year":"2020"},{"key":"2022112912434907100_keac167-B35","author":"Pharmacyclics LLC. IMBRUVICA\u00ae (ibrutinib) [prescribing information]","year":"2020"},{"key":"2022112912434907100_keac167-B36","first-page":"283","article-title":"Ten years of the ESSDAI: is it fit for purpose?","volume":"38(Suppl 126","author":"de Wolff","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2022112912434907100_keac167-B37","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2665-9913(20)30220-4","article-title":"Advances in treatments for Sj\u00f6gren\u2019s syndrome: the glass is half full","volume":"2","author":"Felten","year":"2020","journal-title":"Lancet Rheumatology"},{"key":"2022112912434907100_keac167-B38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/npp.2010.81","article-title":"How placebos change the patient\u2019s brain","volume":"36","author":"Benedetti","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"2022112912434907100_keac167-B39","doi-asserted-by":"crossref","first-page":"E553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2022112912434907100_keac167-B40","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1038\/s41598-020-67462-z","article-title":"Prevalence of Sj\u00f6gren\u2019s syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases","volume":"10","author":"Narv\u00e1ez","year":"2020","journal-title":"Sci Rep"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac167\/43349642\/keac167.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/12\/4797\/47385986\/keac167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/12\/4797\/47385986\/keac167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T07:46:39Z","timestamp":1669707999000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/12\/4797\/6563183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,4,4]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac167","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,4,4]]}}}